478 related articles for article (PubMed ID: 22059904)
21. Bevacizumab and triamcinolone acetonide for choroidal neovascularization due to age-related macular degeneration unresponsive to antivascular endothelial growth factors.
Veritti D; Sarao V; Lanzetta P
J Ocul Pharmacol Ther; 2013 May; 29(4):437-41. PubMed ID: 23215753
[TBL] [Abstract][Full Text] [Related]
22. Effect of a single intravitreal bevacizumab injection on contrast sensitivity and macular thickness in eyes with macular edema from central retinal vein occlusion: a prospective, nonrandomized, three-month follow-up study.
Preti RC; Ramirez LM; Pimentel SL; Nakashima Y; Machado CG; Pelayes DE; Monteiro ML; Takahashi WY
Ophthalmic Res; 2014; 51(3):140-5. PubMed ID: 24525617
[TBL] [Abstract][Full Text] [Related]
23. Short-term results of intravitreal bevacizumab for macular edema with retinal vein obstruction and diabetic macular edema.
Byeon SH; Kwon YA; Oh HS; Kim M; Kwon OW
J Ocul Pharmacol Ther; 2007 Aug; 23(4):387-94. PubMed ID: 17803438
[TBL] [Abstract][Full Text] [Related]
24. Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study.
Rouvas A; Petrou P; Ntouraki A; Douvali M; Ladas I; Vergados I
Retina; 2010 Jun; 30(6):893-902. PubMed ID: 20531142
[TBL] [Abstract][Full Text] [Related]
25. Dexamethasone Intravitreal Implant Rescue Treatment for Bevacizumab Refractory Macular Edema Secondary to Branch Retinal Vein Occlusion.
Lee KH; Kang EC; Koh HJ
Korean J Ophthalmol; 2017 Apr; 31(2):108-114. PubMed ID: 28367038
[TBL] [Abstract][Full Text] [Related]
26. The efficacy of bevacizumab in diabetic macular oedema in a 12-month follow-up.
Jamrozy-Witkowska A; Grabska-Liberek I; Skonieczna K
Klin Oczna; 2014; 116(4):237-41. PubMed ID: 25906633
[TBL] [Abstract][Full Text] [Related]
27. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.
Solaiman KA; Diab MM; Abo-Elenin M
Retina; 2010; 30(10):1638-45. PubMed ID: 20838357
[TBL] [Abstract][Full Text] [Related]
28. Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial.
Zhang H; Liu ZL; Sun P; Gu F
Am J Ophthalmol; 2012 Feb; 153(2):300-306.e1. PubMed ID: 21982109
[TBL] [Abstract][Full Text] [Related]
29. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion.
Pai SA; Shetty R; Vijayan PB; Venkatasubramaniam G; Yadav NK; Shetty BK; Babu RB; Narayana KM
Am J Ophthalmol; 2007 Apr; 143(4):601-6. PubMed ID: 17306753
[TBL] [Abstract][Full Text] [Related]
30. Combined intravitreal bevacizumab and grid laser photocoagulation for macular edema secondary to branch retinal vein occlusion.
Donati S; Barosi P; Bianchi M; Al Oum M; Azzolini C
Eur J Ophthalmol; 2012; 22(4):607-14. PubMed ID: 22101497
[TBL] [Abstract][Full Text] [Related]
31. Effect of intravitreal bevacizumab based on optical coherence tomography patterns of diabetic macular edema.
Kim M; Lee P; Kim Y; Yu SY; Kwak HW
Ophthalmologica; 2011; 226(3):138-44. PubMed ID: 21822008
[TBL] [Abstract][Full Text] [Related]
32. Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization.
Ruiz-Moreno JM; Montero JA; Arias L; Araiz J; Gomez-Ulla F; Silva R; Piñero DP
Retina; 2010; 30(10):1609-15. PubMed ID: 20856171
[TBL] [Abstract][Full Text] [Related]
33. Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group results.
Arevalo JF; Maia M; Garcia-Amaris RA; Roca JA; Sanchez JG; Berrocal MH; Wu L;
Ophthalmology; 2009 Aug; 116(8):1481-7, 1487.e1. PubMed ID: 19545901
[TBL] [Abstract][Full Text] [Related]
34. Intravitreal bevacizumab for inflammatory choroidal neovascularization: results from the Pan-American Collaborative Retina Study Group at 24 months.
Arevalo JF; Adan A; Berrocal MH; Espinoza JV; Maia M; Wu L; Roca JA; Quiroz-Mercado H; Ruiz-Moreno JM; Serrano MA;
Retina; 2011 Feb; 31(2):353-63. PubMed ID: 20890239
[TBL] [Abstract][Full Text] [Related]
35. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Bandello F
Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
[TBL] [Abstract][Full Text] [Related]
36. Comparison of intravitreal triamcinolone acetonide versus intravitreal bevacizumab as the primary treatment of clinically significant macular edema.
Liu Q; Hu Y; Yu H; Yuan L; Hu J; Atik A; Guan M; Li D; Li X; Tang S
Retina; 2015 Feb; 35(2):272-9. PubMed ID: 25105313
[TBL] [Abstract][Full Text] [Related]
37. Visual improvement in central retinal vein occlusion (CRVO) following intravitreal injections of bevacizumab (Avastin(®) ).
Algvere PV; Von Wendt G; Gudmundsson J; Seregard S; Kvanta A
Acta Ophthalmol; 2010 Dec; 88(8):836-41. PubMed ID: 19900206
[TBL] [Abstract][Full Text] [Related]
38. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.
Chan WM; Lai TY; Liu DT; Lam DS
Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414
[TBL] [Abstract][Full Text] [Related]
39. Association of retinal sensitivity and morphology during antiangiogenic treatment of retinal vein occlusion over one year.
Kriechbaum K; Prager F; Geitzenauer W; Benesch T; Schütze C; Simader C; Schmidt-Erfurth U
Ophthalmology; 2009 Dec; 116(12):2415-21. PubMed ID: 19744723
[TBL] [Abstract][Full Text] [Related]
40. Combination therapy with intravitreal bevacizumab and macular grid and scatter laser photocoagulation in patients with macular edema secondary to branch retinal vein occlusion.
Yang CS; Liu JH; Chung YC; Chou YB; Hung KH
J Ocul Pharmacol Ther; 2015 Apr; 31(3):179-85. PubMed ID: 25715024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
